Chondrokalzinosen und sonstige Kristallarthropathien

Kristallarthropathien sind Stoffwechselerkrankungen der Gelenke, deren bekanntester Vertreter die Gicht ist. Daneben existieren jedoch noch eine Reihe weiterer Kristallarthropathien, deren Pathogenese und Therapie sich mitunter deutlich unterscheiden. In diesem Beitrag werden die Entitäten Chondrokalzinose, Apatitkalzinose, Ochronose, Morbus Wilson, Hämochromatose und Oxalose sowie deren Diagnostik und Therapie dargestellt.

• Literatur

• 1 Dihlmann WWM, Stäbler A. Gelenke – Wirbelverbindungen. 4. Aufl. Stuttgart: Thieme; 2010
• 2 Abhishek A, Doherty S, Maciewicz RA et al. Does chondrocalcinosis associate with a distinct radiographic phenotype of osteoarthritis in knees and hips? – a case-control study. Arthritis Care Res (Hoboken) 2016; 68: 211-216
• 3 Frediani B, Filippou G, Falsetti P et al. Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed. Ann Rheum Dis 2005; 64: 638-640
• 4 Shah K, Spear J, Nathanson LA et al. Does the presence of crystal arthritis rule out septic arthritis?. J Emerg Med 2007; 32: 23-26
• 5 De Vere Tyndall A, Hasler P. Rheumatologie. In: Schoenenberger RA, Haefeli WE, Schifferli J, Hrsg. Internistische Notfälle. 8. Aufl. Stuttgart: Thieme; 2008
• 6 Krams M, Frahm SO, Kellner U, Mawrin C Hrsg. Kurzlehrbuch Pathologie. 2. Aufl. Stuttgart: Thieme; 2013
• 7 Ishida T, Dorfman HD, Bullough PG. Tophaceous pseudogout (tumoral calcium pyrophosphate dihydrate crystal deposition disease). Hum Pathol 1995; 26: 587-593
• 8 Zhang W, Doherty M, Bardin T et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70: 563-570
• 9 Ruchholtz S, Wirtz DC Hrsg. Orthopädie und Unfallchirurgie essentials. 2. Aufl. Stuttgart: Thieme; 2012
• 10 Efe T, Sagnak E, Roessler PP et al. Penetration of topical diclofenac sodium 4 % spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trial. Knee Surg Sports Traumatol Arthrosc 2013; 22: 345-350
• 11 Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rheum 1996; 63: 248-254
• 12 Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthrit Cartilage 2007; 15: 981-1000
• 13 Chollet-Janin A, Finckh A, Dudler J et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum 2007; 56: 688-692
• 14 Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther 1997; 23: 327-331
• 15 Zhang W, Doherty M, Pascual E et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011; 70: 571-575
• 16 Doherty M, Dieppe PA. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee. Lancet 1981; 2: 1243-1246
• 17 Checa A, Chun W. Rates of meniscal tearing in patients with chondrocalcinosis. Clin Rheumatol 2015; 34: 573-577
• 18 Carcia CR, Scibek JS. Causation and management of calcific tendonitis and periarthritis. Curr Opin Rheumatol 2013; 25: 204-209
• 19 Serafini G, Sconfienza LM, Lacelli F et al. Rotator cuff calcific tendonitis: short-term and 10-year outcomes after two-needle us-guided percutaneous treatment—nonrandomized controlled trial. Radiology 2009; 252: 157-164
• 20 De Witte PB, Selten JW, Navas A et al. Calcific tendinitis of the rotator cuff: a randomized controlled trial of ultrasound-guided needling and lavage versus subacromial corticosteroids. Am J Sports Med 2013; 41: 1665-1673
• 21 Buchbinder R, Roos J, Johnston R. Shock wave therapy for rotator cuff disease with or without calcification. Cochrane Database Syst Rev 2011; (1) CD008962
• 22 Leduc BE, Caya J, Tremblay S et al. Treatment of calcifying tendinitis of the shoulder by acetic acid iontophoresis: a double-blind randomized controlled trial. Arch Phys Med Rehabil 2003; 84: 1523-1527
• 23 Sell S, Rehart S. Operationsatlas Orthopädische Rheumatologie. Stuttgart: Thieme; 2013
• 24 Toussirot É, Aquaron R. Short-term efficacy of hyaluronic acid joint injections in a case of ochronotic arthropathy. J Clin Rheumatol Pract Reports Rheum Musculoskelet Dis 2013; 19: 152-153
• 25 Suwannarat P, O’Brien K, Perry MB et al. Use of nitisinone in patients with alkaptonuria. Metabolism 2005; 54: 719-728
• 26 Quemeneur A-S, Trocello J-M, Ea H-K et al. Miscellaneous non-inflammatory musculoskeletal conditions. Musculoskeletal conditions associated with Wilsonʼs disease. Best Pract Res Clin Rheumatol 2011; 25: 627-636
• 27 Brewer GJ, Askari FK. Wilsonʼs disease: clinical management and therapy. J Hepatol 2005; 42: 13-21
• 28 Schubert R, Mammsen C. Röntgen- und Szintigrafiebefunde des Skeletts bei Hämochromatose. Fortschr Röntgenstr 2012; 184: 143-145
• 29 Elmberg M, Hultcrantz R, Simard JF et al. Increased risk of arthropathies and joint replacement surgery in patients with genetic hemochromatosis: a study of 3,531 patients and their 11,794 first-degree relatives. Arthritis Care Res (Hoboken) 2013; 65: 678-685
• 30 Arbeitskreises Blut des Bundesministeriums für Gesundheit. Feststellung der Spendereignung und Spendetauglichkeit von Hämochromatose Merkmalsträgern. Bundesgesundheitsbl 2015; 58: 1349-1350
• 31 Phatak P, Brissot P, Wurster M et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010; 52: 1671-1779
• 32 Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol 2013; 66: 367-373